Négrier S, Mercatello A, Coronel B, Merrouche Y, Bret M, Blay J Y, Thiesse P, Clavel M, Moskovtchenko J F, Philip T
Département de Médecine Carcinologique, Centre Léon Bérard, Lyon.
Prog Urol. 1993 Apr;3(2):187-94.
Interleukin 2 (IL2), like Interferon alpha (IFN), is active in metastatic renal cancer, considered to be a chemoresistant cancer. 20 to 30% of objective responses, including 5 to 10% of complete remissions are reported with various protocols of IL2 administration. The considerable toxicity is now well controlled, allowing treatments to be administered in standard wards or even on an outpatient basis by subcutaneous injection. IFN, generally given as long-term treatment, achieved average response rates of between 15 and 20%. Although IL2 and IFN have been granted Product Marketing Authorization in France, the modalities of optimal administration, the place of the combination of IL2-Interferon alpha and the factors predictive of response to treatment still remain unclear.
白细胞介素2（IL2）与α干扰素（IFN）一样，在转移性肾癌中具有活性，转移性肾癌被认为是一种化疗耐药性癌症。据报道，采用各种IL2给药方案时，客观缓解率为20%至30%，其中完全缓解率为5%至10%。目前，相当大的毒性已得到很好的控制，使得治疗可以在标准病房甚至门诊通过皮下注射进行。IFN通常作为长期治疗给药，平均缓解率在15%至20%之间。尽管IL2和IFN在法国已获得产品上市许可，但最佳给药方式、IL2与α干扰素联合使用的地位以及治疗反应的预测因素仍不明确。
